Mineralys Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 24.39 million compared to USD 9.07 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 1.74 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.58 USD | -0.87% |
|
-4.26% | +46.28% |
06-14 | Mineralys Therapeutics, Inc. Announces Changes to its Board | CI |
06-13 | Mineralys Therapeutics Insider Sold Shares Worth $1,252,718, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.28% | 625M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- MLYS Stock
- News Mineralys Therapeutics, Inc.
- Mineralys Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023